PTC Therapeutics, Inc. (NASDAQ: PTCT) is a Healthcare company (Biotechnology) with a market capitalization of $5.0B. The Maz Rating grades it against the other companies in its sector.
PTC Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $60.36, PTC Therapeutics, Inc. trades at 4.4x sales, with an EV/EBITDA of 29.6. Over the last twelve months it generated about $1.1B of revenue and a net loss of $109M. It runs a gross margin of 92.4%, an operating margin of 12.0% and a net margin of -9.2%. It shows return on equity of 57.1%, return on invested capital of 5.7% and a free cash flow yield of -0.8%. On the balance sheet: a debt-to-equity ratio of -3.33 and a current ratio of 3.27. Over the past 52 weeks the share price ranged from $58.80 to $90.87, with a beta of 0.51.
PTC Therapeutics, Inc. does not currently pay a dividend.
26 Wall Street analyst ratings cover the stock: 18 Buy, 6 Hold and 2 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. Its robust pipeline encompasses both commercialized therapies and a variety of experimental drug candidates, spanning all stages of development—from early research and preclinical studies to clinical trials—with a primary focus on addressing various rare disease indications. Among its commercialized products, PTC Therapeutics provides Translarna and Emflaza, offering therapeutic options for Duchenne muscular dystrophy patients in the European Economic Area and the United States. Translarna also addresses nonsense mutation Duchenne muscular dystrophy in Brazil and Russia. The company additionally commercializes Tegsedi and Waylivra for various rare conditions throughout Latin America and the Caribbean. Furthermore, in Brazil, PTC Therapeutics distributes Evrysdi as a treatment for spinal muscular atrophy (SMA) in patients aged two months and older. Leveraging its proprietary splicing platform, the company is also actively developing PTC518, a promising therapeutic candidate aimed at treating Huntington's disease. To bolster its research and development capabilities, PTC Therapeutics has established strategic collaborations, including partnerships with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation, focusing on advancing drug discovery and development research, particularly in regenerative medicine. Additionally, it collaborates with Akcea Therapeutics, Inc. for the commercialization of Tegsedi and Waylivra in the Latin America and Caribbean region. Established in 1998, PTC Therapeutics, Inc. maintains its corporate headquarters in South Plainfield, New Jersey.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, PTC Therapeutics, Inc. (PTCT) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 9.84% / 30% · (Cash+Inv) / Mkt Cap (36m) 39.0% / 30% · Interest income / Revenue 0.00% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 9.84% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 39.0% / 33% · Receivables / Mkt Cap (36m) 4.37% / 49% · Interest income / Revenue 0.00% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 9.84% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 39.0% / 33.33% · Receivables / Mkt Cap (24m) 4.37% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 32.8% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 67.0% / 33.33% · Receivables / Avg Assets (4Q) 7.19% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 16.7% / 33.33% · (Cash+ST Inv) / Total Assets 66.3% / 33.33% · (Cash+Recv) / Total Assets 73.8% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
No. As of September 2026, PTC Therapeutics, Inc. (PTCT) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. PTC Therapeutics, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m).
PTC Therapeutics, Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.